USPTO 2015–2025 USPTO PatentsView US Corporation

Quadriga Biosciences, Inc.

USPTO PatentsView assignee record - 10 granted patents across 6 technology areas, active 2016–2019. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C07F (ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM).

10
Total patents granted
6
CPC technology areas
21.5
Avg claims per patent
-100%
5-year filing velocity

The verdict

Quadriga holds 10 US patents across 6 technology areas, rank #27,197 of 50,000 tracked assignees.

#27,197
of 50,000 US assignees by volume
Top 68%
by Innovation Score (29.8/100)
21.5
avg claims per patent
-100%
filing velocity, last 5 yrs

Portfolio overview

Quadriga Biosciences, Inc. has been granted 10 US utility patents between 2016 and 2019, placing Quadriga Biosciences, Inc. at rank #27,197 across all assignees tracked by PlainPatent. This portfolio spans 6 distinct Cooperative Patent Classification (CPC) subclasses, averaging 21.5 claims per patent with primary concentration in C07F (ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM). As a US Corporation, Quadriga Biosciences, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Quadriga sits between QILU University OF Technology (shandong Academy OF Sciences) (10 patents, rank #27,193) and Quanticel Pharmaceuticals, Inc. (10 patents, rank #27,201) - the closest US assignees by grant volume. The composite Innovation Score of 29.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 0 grants, compared with 10 in the 2015–2019 window, a -100% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Quadriga Biosciences, Inc.'s 21.5 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 6 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Quadriga Biosciences, Inc. against peers pursuing similar technology classes.

Who files at Quadriga's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Quadriga holds 10 patents at rank #27,197, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Quadriga

By rank, the assignees closest to #27,197 in granted patent volume.

Leaders in C07F (Acyclic)

Other assignees with the most granted patents in Quadriga's primary technology class.

Quadriga's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

30 Top 68% higher than 32% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). This entry sits in this band. 40–50: 11,491 US assignees (23%). Above this entry. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

1.522.533.544.5 2016201720182019 2
USPTO utility patent grants by year · 2016–2019

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table
Quadriga Biosciences, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2016 2 20.0%
2017 2 20.0%
2018 4 40.0%
2019 2 20.0%

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Velocity Declining

Where it ranks

Overall rank by patents

#27,197

Across all tracked assignees

Innovation Score

29.8 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Quadriga Biosciences, Inc. hold?
Quadriga Biosciences, Inc. holds 10 US granted patents filed between 2016 and 2019, spanning 6 technology areas.
What is Quadriga Biosciences, Inc.'s Innovation Score?
Quadriga Biosciences, Inc. has an Innovation Score of 29.8 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Quadriga Biosciences, Inc. focus on?
Quadriga Biosciences, Inc.'s top technology area is C07F (ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM) with 10 patents. The company has filed patents in 6 CPC subclasses total.
Is Quadriga Biosciences, Inc.'s patent filing rate increasing or decreasing?
Quadriga Biosciences, Inc.'s recent filing velocity is -100% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Quadriga Biosciences, Inc.'s patents?
Quadriga Biosciences, Inc.'s patents average 21.5 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Quadriga Biosciences, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Quadriga's 10 grants land it in the top 68% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Quadriga ranks #27,197 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in C07F - see who else leads that technology area. C07F leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.